Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1 repotrectinib in ROS1- or NTRK-rearranged advanced solid tumors
NL-OMON60199Phase 2Active, not recruiting
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of repotrectinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoint: Objective Response Rate. Started Dec 2019; status: active, not recruiting.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60199.